A low psoas muscle volume predicts longer hospitalization and cancer recurrence in upper urinary tract urothelial carcinoma

Tsutsumi,Sohgo; Kawahara,Takashi; Teranishi,Jun‑Ichi; Yao,Masahiro; Uemura,Hiroji

doi:10.3892/mco.2017.1537

A low psoas muscle volume predicts longer hospitalization and cancer recurrence in upper urinary tract urothelial carcinoma

Authors:
- Sohgo Tsutsumi
- Takashi Kawahara
- Jun‑Ichi Teranishi
- Masahiro Yao
- Hiroji Uemura
View Affiliations

Affiliations: Department of Urology and Renal Transportation, Yokohama City University Medical Center, Yokohama, Kanagawa 232-0024, Japan, Department of Urology, Yokohama City University, Graduate School of Medicine, Yokohama, Kanagawa 232-0024, Japan
Published online on: December 12, 2017 https://doi.org/10.3892/mco.2017.1537
Pages: 320-322

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aging population is becoming a primary global problem. The most important alteration that occurs in the body with age, is the loss of skeletal muscle. Previously, sarcopenia, which is associated with the loss of skeletal muscle, has been reported to be associated with the prognosis of cancer and complications. The present study investigated the importance of sarcopenia with regard to the prognosis or postoperative complications of upper urothelial cancer patients who underwent nephro‑ureterectomy. A total of sixty patients (male, n=44; female, n=16) underwent nephro-ureterectomy for upper urothelial carcinoma. The psoas muscle volume was calculated at the level of the umbilicus using axial computed tomography images obtained prior to nephro‑ureterectomy. The psoas muscle index (PMI) was calculated by the following formula: (right side psoas muscle area at the level of the umbilicus mm2)/(body height m)2. The median and mean (± standard deviation) ages of the 44 patients were 71 and 68.0 years (± 12.2 years). The lower PMI group demonstrated a significantly poorer recurrence‑free survival compared with the higher PMI group (634 vs. 2,317 days, P=0.005). In terms of the duration of postoperative admission, the long‑admission group (≥13 days) demonstrated a significantly lower PMI compared with the short‑admission group (≤12 days) (383.0 vs. 433.1, P=0.039). Although the overall survival of the two groups did not differ significantly, the lower PMI group tended to have a shorter survival period compared with the higher PMI group (P=0.080). Of the patients with upper urothelial carcinoma, the lower PMI group exhibited a longer postoperative admission period and poorer recurrence‑free survival compared with the higher PMI group. The present findings suggest that sarcopenia is a meaningful factor that should be considered when selecting therapy for upper urothelial carcinoma.

View Figures

View References

1	Cruz-Jentoft AJ, Baeyens JP, Bauer JM, Boirie Y, Cederholm T, Landi F, Martin FC, Michel JP, Rolland Y, Schneider SM, et al: European Working Group on Sarcopenia in Older People: Sarcopenia: European consensus on definition and diagnosis: Report of the European Working Group on Sarcopenia in older people. Age Ageing. 39:412–423. 2010. View Article : Google Scholar : PubMed/NCBI
2	Rosenberg IH: Sarcopenia: Origins and clinical relevance. J Nutr. 127 Suppl 5:990S–991S. 1997.PubMed/NCBI
3	Raman JD, Messer J, Sielatycki JA and Hollenbeak CS: Incidence and survival of patients with carcinoma of the ureter and renal pelvis in the USA, 1973–2005. BJU Int. 107:1059–1064. 2011. View Article : Google Scholar : PubMed/NCBI
4	Rouprêt M, Zigeuner R, Palou J, Boehle A, Kaasinen E, Sylvester R, Babjuk M and Oosterlinck W: European Association of Urology Guideline Group for urothelial cell carcinoma of the upper urinary tract: European guidelines for the diagnosis and management of upper urinary tract urothelial cell carcinomas: 2011 update. European Association of Urology Guideline Group for urothelial cell carcinoma of the upper urinary tract. Actas Urol Esp. 36:2–14. 2012.(In Spanish). View Article : Google Scholar : PubMed/NCBI
5	Oya M and Kikuchi E: Committee for establishment of clinical practice guideline for management of upper tract urothelial carcinoma; japanese urological association: Evidenced-based clinical practice guideline for upper tract urothelial carcinoma (summary-Japanese Urological Association, 2014 edition). Int J Urol. 22:3–13. 2015. View Article : Google Scholar : PubMed/NCBI
6	Hara T, Fujimoto H, Sakura M, Inokuchi J, Nishiyama H, Miyazaki J, Ohyama C, Koie T, Kikuchi E and Hinotsu S; Cancer Registration Committee of the Japanese Urological Association, : Prognostic factors of recurrent disease in upper urinary tract urothelial cancer after radical nephroureterectomy: Subanalysis of the multi-institutional national database of the Japanese Urological Association. Int J Urol. 22:1013–1020. 2015. View Article : Google Scholar : PubMed/NCBI
7	Shiozu H, Higashijima M and Koga T: Association of sarcopenia with swallowing problems, related to nutrition and activities of daily living of elderly individuals. J Phys Ther Sci. 27:393–396. 2015. View Article : Google Scholar : PubMed/NCBI
8	Tanimoto Y, Watanabe M, Sun W, Tanimoto K, Shishikura K, Sugiura Y, Kusabiraki T and Kono K: Association of sarcopenia with functional decline in community-dwelling elderly subjects in Japan. Geriatr Gerontol Int. 13:958–963. 2013. View Article : Google Scholar : PubMed/NCBI
9	Kasahara R, Kawahara T, Ohtake S, Saitoh Y, Tsutsumi S, Teranishi JI, Miyoshi Y, Nakaigawa N, Yao M, Kobayashi K and Uemura H: A Low psoas muscle index before treatment can predict a poorer prognosis in advanced bladder cancer patients who receive gemcitabine and nedaplatin therapy. Biomed Res Int. 2017:79815492017. View Article : Google Scholar : PubMed/NCBI
10	Saitoh-Maeda Y, Kawahara T, Miyoshi Y, Tsutsumi S, Takamoto D, Shimokihara K, Hayashi Y, Mochizuki T, Ohtaka M, Nakamura M, et al: A low psoas muscle volume correlates with a longer hospitalization after radical cystectomy. BMC Urol. 17:872017. View Article : Google Scholar : PubMed/NCBI
11	Zhuang CL, Huang DD, Pang WY, Zhou CJ, Wang SL, Lou N, Ma LL, Yu Z and Shen X: Sarcopenia is an independent predictor of severe postoperative complications and long-term survival after radical gastrectomy for gastric cancer: Analysis from a large-scale cohort. Medicine (Baltimore). 95:e31642016. View Article : Google Scholar : PubMed/NCBI
12	Onesti JK, Wright GP, Kenning SE, Tierney MT, Davis AT, Doherty MG and Chung MH: Sarcopenia and survival in patients undergoing pancreatic resection. Pancreatology. 16:284–289. 2016. View Article : Google Scholar : PubMed/NCBI
13	Makary MA, Segev DL, Pronovost PJ, Syin D, Bandeen-Roche K, Patel P, Takenaga R, Devgan L, Holzmueller CG, Tian J and Fried LP: Frailty as a predictor of surgical outcomes in older patients. J Am Coll Surg. 210:901–908. 2010. View Article : Google Scholar : PubMed/NCBI
14	Bastiampillai R, Lavallée LT, Cnossen S, Witiuk K, Mallick R, Fergusson D, Schramm D, Morash C, Cagiannos I and Breau RH: Laparoscopic nephroureterectomy is associated with higher risk of adverse events compared to laparoscopic radical nephrectomy. Can Urol Assoc J. 10:126–131. 2016. View Article : Google Scholar : PubMed/NCBI
15	Jeldres C, Sun M, Isbarn H, Lughezzani G, Budäus L, Alasker A, Shariat SF, Lattouf JB, Widmer H, Pharand D, et al: A population-based assessment of perioperative mortality after nephroureterectomy for upper-tract urothelial carcinoma. Urology. 75:315–320. 2010. View Article : Google Scholar : PubMed/NCBI